Use of Thiamine supplementation versus placebo on the cardiac function in chronic heart failure patients referred to the cardiology clinic of Imam Khomeini Hospital

Use of Thiamine supplementation versus placebo on the cardiac function in chronic heart failure patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201311019768N2

Enrollment

Registered

2013-11-12

Start date

2013-04-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congestive Heart Failure. Congestive heart disease

Interventions

300 mg Thiamine daily as a single oral tablet

Similar tablet in shape containing placebo. once daily, oral

Intervention 1: 300 mg Thiamine daily as a single oral tablet. Intervention 2: Similar tablet in shape containing placebo. once daily, oral.

Treatment - Drugs

Placebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion: Consent to take part in the study; Treatment with Furosemide; Known case of congestive heart faiure with ejection fraction39 ng/L. Exclusion: 1-Acute heart failure; Vitamine supplementation at the time of first visit; Renal insufficiency (serum creatinine>250 micromol/L; pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ejection fraction increase. Timepoint: 1 month and 3 months after recruitment. Method of measurement: Echocardiography.	—

Secondary

Measure	Time frame
Improvement in the clinical symtoms. Timepoint: 1 and 3 months after recruitment. Method of measurement: Interview and physical excmination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAkbar Shafiee

Tehran Heart Center, Tehran University of Medical Sciences

leo71538@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026